▲Sejung=Announced that with the reappointment of CEO Cheon Ho-jeon, the company has changed to a co-CEO system with Cheon Se-jeon, Kim Ki-baek, and Cheon Ho-jeon serving as individual CEOs.
▲Hanchang Biotech=Announced a name change to Exergy21. Also appointed new CEOs Lee Yong-eung and Shim Hong-gi.
▲Yeon E B&T=Announced the resumption of the orderly liquidation process following the dismissal of the injunction request against the delisting decision.
▲Yulho=Announced a decision to acquire convertible bonds from Paratech worth 10 billion KRW. Stated that they will engage in management if necessary to generate profits through business cooperation.
▲Crystal Genomics=Announced the submission of a multi-center clinical trial plan approval application to the Ministry of Food and Drug Safety for the combination therapy of the anti-PD-1 antibody camrelizumab (SHR-1210) with Pemetrexed and Carboplatin as a first-line treatment for non-small cell lung cancer patients.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
